InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,544.59
(
-0.78%
)
US TECH 100
19,249.60
(
-0.11%
)
Dow Jones
40,665.02
(
-1.29%
)
Brent Oil
84.08
(
-0.48%
)
Bitcoin
63,990.97
(
-0.15%
)
Post# of 252638
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120079
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: stockbettor post# 118643

Thursday, 04/21/2011 2:29:06 PM

Thursday, April 21, 2011 2:29:06 PM

Post# of 252638

BIIB/TEVA/MNTA—Seems to me the more consequential trial will be the second P3 Biogen is running, which includes a Copaxone arm…

It will indeed be more consequential than the first phase-3 trial (where the BG-12 comparator was placebo), but it will not be hugely consequential to Copaxone’s future in the overall scheme of things, IMO. Copaxone’s claim to fame has never been stellar efficacy, but rather its modest efficacy and longstanding safety profile, which spans several decades.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up